Petros Pharmaceuticals, INC 10-Q quarterly reports

Petros Pharmaceuticals, Inc. reported a significant accumulated deficit and substantial doubt regarding its ability to continue as a going concern in its latest quarterly filing.

Petros Pharmaceuticals reports a net loss of $0.99 million for Q1 2026 while continuing to navigate significant going concern risks.

Petros Pharmaceuticals reports significant Q3 losses, Nasdaq delisting, and a strategic pivot to an Rx-to-OTC self-care platform amid substantial doubt about its ability to continue as a going concern.

Petros Pharmaceuticals is transitioning its business focus to an Rx-to-OTC switch technology platform after discontinuing its previous product lines, while also navigating a delisting from Nasdaq and a going concern warning.

Petros Pharmaceuticals reports Q1 2025 results, highlighting a strategic shift towards self-care market innovation amidst ongoing financial and Nasdaq compliance challenges.

Petros Pharmaceuticals' Q3 2024 results reveal a net loss of $2.2 million and a decrease in revenue, alongside ongoing efforts to address financial instability and Nasdaq listing requirements.

Petros Pharmaceuticals experienced a decrease in revenue during the second quarter of 2024, while continuing to pursue its over-the-counter (OTC) strategy for Stendra.

Petros Pharmaceuticals experienced a decrease in revenue during the first quarter of 2024, while continuing its efforts to pursue over-the-counter approval for its erectile dysfunction drug, Stendra.